DEFINING A CYSTIC FIBROSIS GENE WITH RFLP MARKERS

Information

  • Research Project
  • 3236655
  • ApplicationId
    3236655
  • Core Project Number
    R01DK037656
  • Full Project Number
    5R01DK037656-03
  • Serial Number
    37656
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/1986 - 38 years ago
  • Project End Date
    6/30/1990 - 34 years ago
  • Program Officer Name
  • Budget Start Date
    7/1/1988 - 36 years ago
  • Budget End Date
    6/30/1990 - 34 years ago
  • Fiscal Year
    1988
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/3/1988 - 36 years ago

DEFINING A CYSTIC FIBROSIS GENE WITH RFLP MARKERS

We plan to define the cystic fibrosis (CF) gene(s) by the use of polymorphic DNA markers (RFLPs) in genetic linkage studies. We have identified one such marker (DOCRI-917) genetically linked to a cystic fibrosis locus at a distance of 15 centimorgans (cM) (about 15 million nucleotide basepairs). We plan to 1) expand the informativeness (i.e. the polymorphism) at or near the existing marker, DOCRI-917, and to physically map the locus and thereby the CF gene itself, 2) to identify additional DNA polymorphisms closer and flanking the CF locus by the construction of a genetic linkage map of the chromosome on which the CF locus resides using the set of over 500 polymorphic DNA probes we have already identified as well as new chromosome specific probes we plan to isolate, 3) to investigate the possibility of genetic heterogeneity of CF, i.e. determine the number of genes which, when homozygous, cause the disease by analysis of a larger set of CF families and 4) if definitive evidence is found for additional CF genes, we plan to use our large set of polymorphic probes to detect linkage to these additional genes. These studies will open the way for all types of molecular approaches leading to more narrowly defining the chromosomal locus for CF. This will eventually lead to identification of the CF gene(s) and the molecular defect(s) responsible for the disease. An application of these studies will be the development of presymptomatic diagnostic tests for cystic fibrosis.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R01
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    MGN
  • Study Section Name
    Mammalian Genetics Study Section
  • Organization Name
    COLLABORATIVE RESEARCH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    WALTHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02154
  • Organization District
    UNITED STATES